SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis
<p>HONG KONG SAR - <a href="https://www.media-outreach.com/">Media OutReach</a> - 26 April 2023 - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - <b>SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company")</b>, is pleased to announce that Phase III clinical trial of SinoMab's flagship product SM03 (Suciraslimab) for rheumatoid arthritis (RA) in China (Study No.</p>
Source: whatech.com